Lightnews — Scholar-powered news

Alberto Mussetti @albertomussetti.bsky.social · 16d

CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis | New England Journal of Medicine DOI: 10.1056/NEJMc2508023

Alberto Mussetti @albertomussetti.bsky.social · 23d

24th OCT 2025 - Barcelona

Join the #1 edition of "AICT: Artificial Intelligence & Cell Therapy" – where tech meets hematology 🧠🧬
🚀 free inscription, In-person and online.

#AICT2025 #CellTherapy #AIinMedicine #FutureIsNow #CART #HCT #digitalhealth #digitalrevolution

lnkd.in/dBDXnaSK

www.geth.es

Alberto Mussetti @albertomussetti.bsky.social · 23d

mRNA for CART manufacturing for LES...

www.nejm.org/doi/full/10....

In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus | NEJM

In patients with refractory systemic lupus erythematosus, in vivo generation of CD19 CAR T cells by means of lipid nanoparticles led to B-cell depletion, reduced disease activity, and no major toxi...

www.nejm.org

Alberto Mussetti @albertomussetti.bsky.social · Sep 11

Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT url: ashpublications.org/blood/articl...

Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT

Key PointsAugmented CD47 expression on alloreactive donor T cells after HCT inhibits their phagocytosis by macrophages.Anti-CD47 treatment boosts phagocyto

ashpublications.org

Alberto Mussetti @albertomussetti.bsky.social · Sep 11

Transformative Research in Cystic Fibrosis | New England Journal of Medicine www-nejm-org.sire.ub.edu/doi/full/10....

Shibboleth Authentication Request

www-nejm-org.sire.ub.edu

Alberto Mussetti @albertomussetti.bsky.social · Sep 4

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies url: ashpublications.org/blood/articl...

Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies

Key PointsWU-CART-007, an allogeneic anti-CD7 chimeric antigen receptor T cell, established a manageable safety profile at the RP2D of 900 × 106 cells.WU-C

ashpublications.org

1

Alberto Mussetti @albertomussetti.bsky.social · Sep 2

ashpublications.org/bloodadvance...

A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept

Key PointsPTCy+Aba arm is associated with less chronic GVHD and a favorable GRFS compared with methotrexate/tacrolimus.PTCy and Aba without a calcineurin i

ashpublications.org

Alberto Mussetti @albertomussetti.bsky.social · Aug 28

Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma url: ashpublications.org/blood/articl...

Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma

Key PointsDespite similar CAR T-cell dynamics, patients with SLE experienced less severe adverse events after CAR T-cell therapy than those with B-NHL.In p

ashpublications.org

1

Alberto Mussetti @albertomussetti.bsky.social · Aug 27

www.cell.com/cancer-cell/...

Lymphoma accelerates T cell and tissue aging

Hesterberg et al. show that lymphoma provokes marked and rapid changes in young T cells that recapitulate the transcriptional, epigenetic, and senescent features manifest in aged T cells, including ag...

www.cell.com

Alberto Mussetti @albertomussetti.bsky.social · Aug 25

www.mdanderson.org/newsroom/nov...

Novel tool helps identify key targets to strengthen CAR NK cell therapies

Natural killer (NK) cells became markedly better at killing cancer cells after scientists removed key gene targets identified through a new genome-wide CRISPR screening tool, according to new research...

www.mdanderson.org

Alberto Mussetti @albertomussetti.bsky.social · Aug 25

www.nytimes.com/2025/08/25/m...

What Does It Take to Get Men to See a Doctor?

www.nytimes.com

Alberto Mussetti @albertomussetti.bsky.social · Aug 20

www.nejm.org/doi/full/10....

Educational Strategies for Clinical Supervision of Artificial Intelligence Use | NEJM

Many learners are more facile with the use of large language models in medicine than their supervisors are. The authors provide an approach to clinical supervision that can mitigate the perils and ...

www.nejm.org

Alberto Mussetti @albertomussetti.bsky.social · Aug 20

www.nejm.org/doi/full/10....

Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy | NEJM

A rare T-cell lymphoma after chimeric antigen receptor (CAR) T-cell therapy for myeloma was linked to CCR4 overexpression and vector integration, which highlights the need for monitoring after CAR ...

www.nejm.org

Alberto Mussetti @albertomussetti.bsky.social · Aug 10

jitc.bmj.com/content/13/8...

Zelig Eshhar (1941–2025): a tribute for a life for immunotherapy

Zelig Eshhar, PhD, Fellow of the Academy of Immuno-Oncology (FAIO), passed away on July 3, 2025, at the age of 84. His passing is deeply personal to all of us and for the entire field of cancer immuno...

jitc.bmj.com

Alberto Mussetti @albertomussetti.bsky.social · Aug 5

www.ara.cat/1_535642

Que la IA et diagnostiqui: el ChatGPT que ja fa servir el teu metge

L'eina estarà a prova aquest any per donar suport als professionals sanitaris en la presa de decisions

www.ara.cat

Alberto Mussetti @albertomussetti.bsky.social · Aug 4

www.nytimes.com/2025/08/04/o...

Opinion | You Are Contaminated

www.nytimes.com

Alberto Mussetti @albertomussetti.bsky.social · Aug 3

www.nytimes.com/2025/07/31/w...

Could Dementia Patients Benefit from an A.I. Companion?

www.nytimes.com

Alberto Mussetti @albertomussetti.bsky.social · Jul 31

Heterogeneity of high-potency multilineage hematopoietic stem cells and identification of “Super” transplantability url: ashpublications.org/blood/articl...

Heterogeneity of high-potency multilineage hematopoietic stem cells and identification of “Super” transplantability

Key PointsUnique molecular features of Super-class HSCs were identified through analyses of single-clone serial transplants.Low expression of CD27 is a key

ashpublications.org

Alberto Mussetti @albertomussetti.bsky.social · Jul 28

Dear friends and colleagues,

We would love to have you join this year’s Transplant Complications Working Party Educational Meeting in Dubrovnik, Croatia, on the 1st-3rd of October. The EBMT

More information here:

www.ebmt.org/events/trans...

We look forward to seeing you in Dubrovnik!

This link will take you to a page that’s not on LinkedIn

lnkd.in

Alberto Mussetti @albertomussetti.bsky.social · Jul 24

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia url: ashpublications.org/blood/articl...

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia

Key PointsLS, an emergent form of acute leukemia relapse after antigen-targeted therapy, primarily in B-ALL, has dismal outcomes.LS arises rapidly after im

ashpublications.org

Alberto Mussetti @albertomussetti.bsky.social · Jul 24

Itacitinib for the prevention of IEC therapy–associated CRS: results from the 2-part phase 2 INCB 39110-211 study url: ashpublications.org/blood/articl...

Itacitinib for the prevention of IEC therapy–associated CRS: results from the 2-part phase 2 INCB 39110-211 study

Key PointsProphylactic itacitinib (200 mg) twice daily was effective in preventing CRS and ICANS in patients who underwent CD19-directed IEC therapy.Prophy

ashpublications.org